Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?

John M. Strother, Tomasz M. Beer, Robert Dreicer

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


In 2004, docetaxel-based chemotherapy became the first treatment capable of extending life in androgen-independent prostate cancer. The era of therapeutic nihilism in this disease has thus been put to rest and a broad range of agents is being tested with the goal of improving on the successes of 2004. Lessons learned from other tumour types will need to be applied to prostate cancer in order to harness the bounty of available ideas. Target amplification or activating mutations and not merely the presence of a target are likely to be important to the success of targeted agents. Thus, the promise of the current crop of targeted agents is most likely to be realised when pursued in the context of well-credentialed targets and tested in highly translational clinical trials that are capable not only of assessing tumour response, but also of evaluating the status of the targeted pathway. The most promising agents in clinical development are reviewed.

Original languageEnglish (US)
Pages (from-to)954-964
Number of pages11
JournalEuropean Journal of Cancer
Issue number6
StatePublished - Apr 2005


  • Chemotherapy
  • Novel agents
  • Prostate cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005?'. Together they form a unique fingerprint.

Cite this